Organisation paid for research Program year 2025 Source: CMS Open Payments

Oklahoma Heart Hospital South Campus

Neither a doctor nor a teaching hospital

Research payments

$348,118

223 payments

Through program year 2025, Oklahoma Heart Hospital South Campus is reported as receiving $348,118 in research payments, across 223 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$8,300	1
2024	Research	$16,875	1
2023	Research	$21,156	4
2022	Research	$40,267	4
2021	Research	$77,254	59
2020	Research	$184,243	153
2019	Research	$23	1

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim International GmbH $223,985 203 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $65,468 14 payments
AstraZeneca Pharmaceuticals LP $58,620 4 payments
Abbott Laboratories $23 1 payment
Boehringer Ingelheim Pharmaceuticals, Inc. $22 1 payment

Studies the money was for Research payments · program years 2019–2025

Empagliflozin and heart failure (HFpEF) $195,783 169 payments
Dapagliflozin in Acute Decompensated Heart Failure $58,620 4 payments
Empagliflozin and Heart failure (HFrEF) $41,035 38 payments
Empagliflozin for prevention of HHF and death afte $21,830 3 payments
Empagliflozin for prevention of HHF and death after an AMI $18,579 2 payments
Safety & Efficacy of Empa in patients with Acute HF $6,099 3 payments
Empagliflozin and heart failure HFpEF $6,000 1 payment
Obesity Long term safety in patients with CV risk $148 2 payments
Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) $23 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.